Emerging research suggests that popular GLP-1 drugs, known for mainly weight loss and diabetes management, may also slow the progression of various types of cancer.
| PULSE POINTS |
❓ WHAT HAPPENED: Weight-loss drugs like Ozempic could slow the progression of cancer in patients, according to recent studies. 📰 DETAIL: According to a new series of studies, GLP-1 weight-loss drugs, such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, can reduce cancer progression and mortality rates. One study of 10,000 patients, all with different types of cancer, done by the Cleveland Clinic Cancer Institute, observed a significant reduction in cancer progression among the patients. Lung cancer progression was halved in patients who took GLP-1 drugs, while the progression of breast cancer decreased by 43 percent. The studies were observational, meaning they used medical records to establish an association between taking the drugs and reduced cancer progression, rather than conducting controlled medical trials. While the findings have not been published in a peer-reviewed journal, they will be presented to the American Society of Clinical Oncology at the society’s annual meeting next week. At present, GLP-1 drugs are used to manage weight, diabetes, kidney and heart disease, and obstructive sleep apnea. 💬 KEY QUOTE: “It’s really provocative that they showed, in several cancers, that people who took these drugs seem to have a lower risk of their cancer returning.” – Dr. Jennifer Ligibel, breast oncologist at the Dana-Farber Cancer Institute 🎯 IMPACT: While observational, the studies suggest that weight-loss drugs could be used to fight cancer. GLP-1 drugs are normally used to treat diabetes and weight management. The findings could lead to controlled medical trials to establish a more reliable connection between reduced progression and GLP-1 drugs. Further positive findings could heavily influence the pharmaceutical market, given that such drugs are already growing in popularity. |
Image by Dennis Sylvester Hurd.
Join Pulse+ to comment below, and receive exclusive e-mail analyses.